A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With or Without Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients

Trial Profile

A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With or Without Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Gemcitabine (Primary) ; Ubidecarenone (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Berg Pharma
  • Most Recent Events

    • 04 Apr 2018 According to a Berg Pharma media release, the first patient has been dosed in the United Kingdom (UK) for this study. Company is planning to advance this study into other European countries in 2018.
    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Sep 2017 Results presented at the European Society for Medical Oncology (ESMO) 2017 Congress, according to a BERG media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top